In 2010 the first clinical trial of CAR-T therapy was reported, using second-gen CARs and targeted at CD19 in non-Hodkin’s lymphoma, a blood cancer. CD19 is still the predominant CAR-T cell target under investigation.
In 2010 the first clinical trial of CAR-T therapy was reported, using second-gen CARs and targeted at CD19 in non-Hodkin’s lymphoma, a blood cancer. CD19 is still the predominant CAR-T cell target under investigation.